Oncology Molecular Diagnostics Market Size, Share, Trends, Growth Outlook

Oncology Molecular Diagnostics Market is estimated to increase at a growth rate of 12.5% CAGR over the forecast period from 2024 to 2030.

The global Oncology Molecular Diagnostics Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Product (Instrument, Reagents, Others), By Technology (Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), DNA Sequencing and Next-Generation Sequencing, In-situ Hybridization, Mass Spectrometry, Transcription Mediated Amplification (TMA), Chips and Microarrays, Others), By Application (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, Blood Cancer, Liver Cancer, Cervical Cancer, Others), By End-User (Hospitals, Diagnostic Centers, Others).

An Introduction to Oncology Molecular Diagnostics Market in 2024

Molecular diagnostics play a pivotal role in guiding precision medicine approaches and personalized cancer care, driving significant growth and innovation in the Oncology Molecular Diagnostics Market in 2024. With advancements in genomics, proteomics, and liquid biopsy technologies, there is growing demand for molecular diagnostic tests capable of detecting genetic alterations, predicting treatment response, and monitoring disease progression in cancer patients. The market is witnessing rapid expansion with the development and commercialization of next-generation sequencing (NGS) assays, polymerase chain reaction (PCR) tests, and multiplexed biomarker panels targeting key oncogenic mutations, fusion genes, and immune signatures across various cancer types. Moreover, there is increasing adoption of companion diagnostics, circulating tumor DNA (ctDNA) assays, and digital pathology platforms in clinical practice, facilitating precise tumor profiling and treatment decision-making in oncology. As oncology molecular diagnostics continue to evolve, they hold promise for revolutionizing cancer diagnosis, prognosis, and therapeutic management, empowering oncologists with actionable insights to deliver personalized and targeted therapies to cancer patients.

Oncology Molecular Diagnostics Market Competitive Landscape

The global Oncology Molecular Diagnostics Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Oncology Molecular Diagnostics Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Oncology Molecular Diagnostics Industry include- Abbott Laboratories, Agilient Technologies Inc, bioMérieux SA, Danaher Corp, F. Hoffmann La-Roche Ltd, HTG Molecular Diagnostics Inc, Illumina Inc, QIAGEN N.V., Sysmex Corp, TBG Diagnostics Ltd, Thermo Fisher Scientific Inc, Veracyte Inc.

Oncology Molecular Diagnostics Market Trend: Advancements in Next-Generation Sequencing (NGS) Technologies

In the Oncology Molecular Diagnostics market, a prominent trend is the advancements in Next-Generation Sequencing (NGS) technologies. NGS technologies have revolutionized the field of oncology by enabling comprehensive and high-throughput analysis of tumor genomes, transcriptomes, and epigenomes. These advancements allow for the identification of genetic alterations, including mutations, copy number variations, and gene fusions, that drive cancer initiation, progression, and response to therapy. NGS-based molecular diagnostics provide oncologists with valuable insights into tumor biology, guiding treatment decisions, predicting treatment response, and monitoring disease progression. Additionally, the development of targeted NGS panels and liquid biopsy assays offers the potential for non-invasive detection of circulating tumor DNA (ctDNA) and tumor-derived biomarkers, facilitating early cancer detection, minimal residual disease monitoring, and assessment of treatment resistance. As NGS technologies continue to evolve, becoming more cost-effective, rapid, and accessible, they play an increasingly integral role in precision oncology and personalized cancer care, driving innovation and market growth in Oncology Molecular Diagnostics.

Oncology Molecular Diagnostics Market Driver: Precision Medicine and Targeted Therapy Adoption

The primary market driver for Oncology Molecular Diagnostics is the adoption of precision medicine and targeted therapy approaches in cancer treatment. Precision medicine aims to tailor medical interventions, including drug therapies, to the individual characteristics of each patient, considering factors such as genetic makeup, tumor biology, and molecular profiling. Molecular diagnostics play a pivotal role in precision oncology by providing actionable information about tumor-specific genetic alterations and biomarkers that can guide treatment selection and optimization. Oncologists use molecular diagnostic tests to stratify patients into subgroups based on their molecular profiles, allowing for the selection of targeted therapies that are most likely to be effective against specific tumor types or molecular subtypes. Moreover, molecular diagnostics enable the identification of patients who may benefit from immunotherapy, hormonal therapy, or combination therapies, optimizing treatment outcomes and minimizing the risk of adverse effects. As targeted therapies and immunotherapies become increasingly integrated into standard cancer care pathways, the demand for molecular diagnostic testing continues to rise, driving market expansion and investment in Oncology Molecular Diagnostics.

Oncology Molecular Diagnostics Market Opportunity: Integration of Artificial Intelligence (AI) and Machine Learning

An emerging opportunity in the Oncology Molecular Diagnostics market lies in the integration of Artificial Intelligence (AI) and machine learning algorithms to enhance data analysis and interpretation. The complexity and volume of data generated by NGS and molecular profiling technologies present challenges for data analysis and interpretation, requiring advanced computational tools and bioinformatics algorithms to extract meaningful insights from genomic, transcriptomic, and proteomic datasets. AI and machine learning techniques offer the potential to automate and streamline data analysis workflows, identify patterns, and predict treatment response or disease prognosis based on molecular signatures and clinical data. By leveraging AI-driven analytics platforms, molecular diagnostic laboratories can accelerate the interpretation of complex genomic data, improve diagnostic accuracy, and provide actionable insights to oncologists in real-time. Furthermore, AI-powered decision support tools can facilitate the integration of molecular diagnostic results into clinical practice, enabling personalized treatment recommendations and optimizing patient care pathways. Collaborative efforts between diagnostic companies, bioinformatics providers, and healthcare institutions are essential for developing and validating AI-driven solutions that enhance the utility and impact of Oncology Molecular Diagnostics in precision oncology.

Oncology Molecular Diagnostics Market Share Analysis: Next-Generation Sequencing (NGS) Technology is the fastest growing market segment over the forecast period to 2030

Among the various technologies used in oncology molecular diagnostics, Next-Generation Sequencing (NGS) emerges as the fastest-growing segment. This growth is driven by significant advancements in sequencing technology, which have revolutionized the field of cancer genomics by enabling comprehensive and high-throughput analysis of tumor genomes. NGS allows for the simultaneous sequencing of millions of DNA fragments, providing detailed information about genetic alterations, such as mutations, copy number variations, and chromosomal rearrangements, that drive cancer development and progression. In oncology, NGS plays a critical role in precision medicine by guiding treatment decisions, predicting therapeutic responses, and identifying targeted therapy options tailored to the molecular profile of individual tumors. Moreover, NGS-based liquid biopsy assays have emerged as promising tools for non-invasive detection of tumor-derived DNA in blood or other bodily fluids, offering a minimally invasive and real-time approach for monitoring treatment response and detecting the emergence of drug resistance in cancer patients. As the cost of NGS technology continues to decline and its analytical capabilities improve, its adoption in oncology molecular diagnostics is expected to continue its rapid growth trajectory, driving personalized cancer care and contributing to improved outcomes for patients with various malignancies.

Oncology Molecular Diagnostics Market Segmentation

By Product
Instrument
Reagents
Others
By Technology
Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
DNA Sequencing and Next-Generation Sequencing
In-situ Hybridization
Mass Spectrometry
Transcription Mediated Amplification (TMA)
Chips and Microarrays
Others
By Application
Breast Cancer
Prostate Cancer
Colorectal Cancer
Lung Cancer
Blood Cancer
Liver Cancer
Cervical Cancer
Others
By End-User
Hospitals
Diagnostic Centers
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Oncology Molecular Diagnostics Companies

Abbott Laboratories
Agilient Technologies Inc
bioMérieux SA
Danaher Corp
F. Hoffmann La-Roche Ltd
HTG Molecular Diagnostics Inc
Illumina Inc
QIAGEN N.V.
Sysmex Corp
TBG Diagnostics Ltd
Thermo Fisher Scientific Inc
Veracyte Inc
* List not Exhaustive

Reasons to Buy the Oncology Molecular Diagnostics Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Oncology Molecular Diagnostics Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Oncology Molecular Diagnostics Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Oncology Molecular Diagnostics Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Oncology Molecular Diagnostics Market Size Outlook, $ Million, 2021 to 2030
3.2 Oncology Molecular Diagnostics Market Outlook by Type, $ Million, 2021 to 2030
3.3 Oncology Molecular Diagnostics Market Outlook by Product, $ Million, 2021 to 2030
3.4 Oncology Molecular Diagnostics Market Outlook by Application, $ Million, 2021 to 2030
3.5 Oncology Molecular Diagnostics Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Oncology Molecular Diagnostics Industry
4.2 Key Market Trends in Oncology Molecular Diagnostics Industry
4.3 Potential Opportunities in Oncology Molecular Diagnostics Industry
4.4 Key Challenges in Oncology Molecular Diagnostics Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Oncology Molecular Diagnostics Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Oncology Molecular Diagnostics Market Outlook by Segments
7.1 Oncology Molecular Diagnostics Market Outlook by Segments, $ Million, 2021- 2030
By Product
Instrument
Reagents
Others
By Technology
Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
DNA Sequencing and Next-Generation Sequencing
In-situ Hybridization
Mass Spectrometry
Transcription Mediated Amplification (TMA)
Chips and Microarrays
Others
By Application
Breast Cancer
Prostate Cancer
Colorectal Cancer
Lung Cancer
Blood Cancer
Liver Cancer
Cervical Cancer
Others
By End-User
Hospitals
Diagnostic Centers
Others
8 North America Oncology Molecular Diagnostics Market Analysis and Outlook To 2030
8.1 Introduction to North America Oncology Molecular Diagnostics Markets in 2024
8.2 North America Oncology Molecular Diagnostics Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Oncology Molecular Diagnostics Market size Outlook by Segments, 2021-2030
By Product
Instrument
Reagents
Others
By Technology
Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
DNA Sequencing and Next-Generation Sequencing
In-situ Hybridization
Mass Spectrometry
Transcription Mediated Amplification (TMA)
Chips and Microarrays
Others
By Application
Breast Cancer
Prostate Cancer
Colorectal Cancer
Lung Cancer
Blood Cancer
Liver Cancer
Cervical Cancer
Others
By End-User
Hospitals
Diagnostic Centers
Others
9 Europe Oncology Molecular Diagnostics Market Analysis and Outlook To 2030
9.1 Introduction to Europe Oncology Molecular Diagnostics Markets in 2024
9.2 Europe Oncology Molecular Diagnostics Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Oncology Molecular Diagnostics Market Size Outlook by Segments, 2021-2030
By Product
Instrument
Reagents
Others
By Technology
Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
DNA Sequencing and Next-Generation Sequencing
In-situ Hybridization
Mass Spectrometry
Transcription Mediated Amplification (TMA)
Chips and Microarrays
Others
By Application
Breast Cancer
Prostate Cancer
Colorectal Cancer
Lung Cancer
Blood Cancer
Liver Cancer
Cervical Cancer
Others
By End-User
Hospitals
Diagnostic Centers
Others
10 Asia Pacific Oncology Molecular Diagnostics Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Oncology Molecular Diagnostics Markets in 2024
10.2 Asia Pacific Oncology Molecular Diagnostics Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Oncology Molecular Diagnostics Market size Outlook by Segments, 2021-2030
By Product
Instrument
Reagents
Others
By Technology
Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
DNA Sequencing and Next-Generation Sequencing
In-situ Hybridization
Mass Spectrometry
Transcription Mediated Amplification (TMA)
Chips and Microarrays
Others
By Application
Breast Cancer
Prostate Cancer
Colorectal Cancer
Lung Cancer
Blood Cancer
Liver Cancer
Cervical Cancer
Others
By End-User
Hospitals
Diagnostic Centers
Others
11 South America Oncology Molecular Diagnostics Market Analysis and Outlook To 2030
11.1 Introduction to South America Oncology Molecular Diagnostics Markets in 2024
11.2 South America Oncology Molecular Diagnostics Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Oncology Molecular Diagnostics Market size Outlook by Segments, 2021-2030
By Product
Instrument
Reagents
Others
By Technology
Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
DNA Sequencing and Next-Generation Sequencing
In-situ Hybridization
Mass Spectrometry
Transcription Mediated Amplification (TMA)
Chips and Microarrays
Others
By Application
Breast Cancer
Prostate Cancer
Colorectal Cancer
Lung Cancer
Blood Cancer
Liver Cancer
Cervical Cancer
Others
By End-User
Hospitals
Diagnostic Centers
Others
12 Middle East and Africa Oncology Molecular Diagnostics Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Oncology Molecular Diagnostics Markets in 2024
12.2 Middle East and Africa Oncology Molecular Diagnostics Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Oncology Molecular Diagnostics Market size Outlook by Segments, 2021-2030
By Product
Instrument
Reagents
Others
By Technology
Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
DNA Sequencing and Next-Generation Sequencing
In-situ Hybridization
Mass Spectrometry
Transcription Mediated Amplification (TMA)
Chips and Microarrays
Others
By Application
Breast Cancer
Prostate Cancer
Colorectal Cancer
Lung Cancer
Blood Cancer
Liver Cancer
Cervical Cancer
Others
By End-User
Hospitals
Diagnostic Centers
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott Laboratories
Agilient Technologies Inc
bioMérieux SA
Danaher Corp
F. Hoffmann La-Roche Ltd
HTG Molecular Diagnostics Inc
Illumina Inc
QIAGEN N.V.
Sysmex Corp
TBG Diagnostics Ltd
Thermo Fisher Scientific Inc
Veracyte Inc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Product
Instrument
Reagents
Others
By Technology
Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
DNA Sequencing and Next-Generation Sequencing
In-situ Hybridization
Mass Spectrometry
Transcription Mediated Amplification (TMA)
Chips and Microarrays
Others
By Application
Breast Cancer
Prostate Cancer
Colorectal Cancer
Lung Cancer
Blood Cancer
Liver Cancer
Cervical Cancer
Others
By End-User
Hospitals
Diagnostic Centers
Others